Neurocrine Biosciences (NBIX) Cash from Operations Growth (5y) (2015 - 2026)
Neurocrine Biosciences (NBIX) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.74% |
| Mar 31, 2026 | 10.80% |
| Dec 31, 2025 | 32.67% |
| Sep 30, 2025 | 67.42% |
| Jun 30, 2025 | -3.02% |
| Mar 31, 2025 | 12.79% |
| Dec 31, 2024 | 19.99% |
| Sep 30, 2024 | 10.07% |
| Jun 30, 2024 | 0.12% |
| Mar 31, 2024 | 25.86% |
| Dec 31, 2023 | 19.59% |
| Sep 30, 2023 | 25.20% |
| Jun 30, 2023 | 54.38% |
| Mar 31, 2023 | -26.61% |
| Dec 31, 2022 | 28.65% |
| Sep 30, 2022 | 66.02% |
| Jun 30, 2022 | 37.21% |
| Mar 31, 2022 | 12.14% |
| Dec 31, 2021 | 16.36% |
| Sep 30, 2021 | 31.90% |